NBRVライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (1 8月 2023 @ 05:00):

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections...

Stats
本日の出来高	706 536
平均出来高	13 843.00
時価総額	4.55M
EPS	$-4.50 ( 2023-08-10 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.0722
ATR14	$0.181 (28.73%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-06	Hogan H Michael Iii	Buy	0
2023-06-30	Maggio David	Buy	0
2023-01-29	Gelone Steven P.	Sell	140	Ordinary Shares
2023-01-29	Schroeder Theodore R	Sell	431	Ordinary Shares
2023-01-06	Gelone Steven P.	Sell	5	Ordinary Shares

INSIDER POWER
20.49
Last 98 transactions
Buy: 1 927 900 \| Sell: 612 376

ボリューム相関

長: 0.06 (neutral)

短: 0.60 (weak)

Signal:(34.114) Neutral

Nabriva Therapeutics PLC 相関

10 最も正の相関

10 最も負の相関

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Nabriva Therapeutics PLC 相関 - 通貨/商品

-0.32
( neutral )

-0.83
( strong negative )

0.00
( neutral )

-0.51
( weak negative )

0.33
( neutral )

0.26
( neutral )

Nabriva Therapeutics PLC 財務諸表

Annual	2022
収益:	$35.67M
総利益:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2022
収益:	$35.67M
総利益:	$7.09M (19.87 %)
EPS:	$-21.32

FY	2021
収益:	$28.90M
総利益:	$15.75M (54.50 %)
EPS:	$-96.24

FY	2020
収益:	$2.86M
総利益:	$2.10M (73.25 %)
EPS:	$-135.23

Financial Reports:

No articles found.

Nabriva Therapeutics PLC

Nabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired bacterial pneumonia. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, hospital-acquired bacterial pneumonia, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.